Comparison · NCT03198507-7b8eed54
RHB-105 vs Active Comparator: Number of Participants With Eradication of H. Pylori
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. RHB-105 vs Active Comparator: Number of Participants With Eradication of H. Pylori. Trial comparisons, record NCT03198507-7b8eed54. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03198507-7b8eed54
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.838 | 0.784 | 0.88 | wilson | |
| Risk in group 2 | 0.577 | 0.512 | 0.64 | wilson | |
| Risk difference, group 1 minus group 2 | 0.261 | 0.178 | 0.338 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.45 | 1.28 | 1.65 | log | |
| Odds ratio, group 1 over group 2 | 3.78 | 2.44 | 5.87 | log | |
| Number needed to treat, for one more participant with the outcome on RHB-105 than on Active Comparator | 3.84 | 2.96 | 5.6 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | RHB-105 | RHB-105 (Rifabutin 150 mg, Amoxicillin 3000 mg, Omeprazole 120 mg) | 191 | 228 | OG000 |
| Group 2 | Active Comparator | Active comparator (Amoxicillin 3000 mg, Omeprazole 120 mg) | 131 | 227 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Eradication of H. Pylori
- Description
Eradication of H. pylori confirmed via 13C Urea Breath Test (UBT) testing. Subjects with negative test results (eradication of H. pylori) were considered treatment successes. Subjects who tested positive for H. pylori infection (no eradication) were considered treatment failures.
- Time frame
- 43-71 days after initiation of treatment
- Population
- Full Analysis Set (FAS)
Source ClinicalTrials.gov
Trial
- Title
- ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator
- NCT number
- NCT03198507
- Phases
- PHASE3
- Conditions
- Helicobacter Pylori Infection, Dyspepsia
- Interventions
- RHB-105, Active Comparator
- Lead sponsor
- RedHill Biopharma Limited
- Results first posted
- 2020-03-16
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03198507?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03198507-7b8eed54